Retractable Technologies, Inc. — Q1 2022 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2022, compared with Q1 2021. The company designs, manufactures and markets safety syringes and other medical products. VanishPoint syringes represented 95.4% of sales.
Key financial results
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $44.7 million | $50.1 million | Down 10.6% |
| Gross profit / margin | $15.6 million / 34.8% | $28.0 million / 55.9% | Profit down 44.4% |
| Operating income / margin | $9.7 million / 21.7% | $23.4 million / 46.8% | Down 58.5% |
| Net income | $7.6 million | $18.0 million | Down 57.6% |
| Net income applicable to common shareholders | $7.6 million | $17.9 million | Down 57.7% |
| Diluted EPS | $0.23 | $0.52 | Down $0.29 |
| Cash from operations | $21.4 million | $16.6 million | Up 29.1% |
Balance sheet and liquidity: Cash was $43.1 million at March 31, up from $29.2 million at year-end; investments in debt and equity securities were $18.7 million. Current assets were $106.5 million and current liabilities $28.4 million, for working capital of about $78.1 million. Long-term debt, including current maturities, was approximately $2.0 million. Other long-term liabilities included $72.0 million related to the government-funded Technology Investment Agreement (TIA); this is separate from debt. Total liabilities were $102.2 million and stockholders’ equity $105.3 million.
Operating cash flow benefited principally from a $15.3 million decrease in receivables and included a $5.1 million deferred-tax adjustment. Investing activities used $7.1 million, including $5.0 million for property and equipment. Financing activities used $0.4 million, including $2.5 million for common-stock repurchases. Management stated it expects sufficient resources for short- and long-term needs, including cash, operating receipts and investments available for sale.
Material changes and management commentary
- Domestic revenue fell 46.8%, primarily because U.S. government sales declined to $15.7 million from $37.8 million. Government sales were 35.2% of Q1 2022 sales, versus 75.5% of sales to significant customers in Q1 2021.
- International revenue rose sharply, principally from purchases by a non-governmental humanitarian organization for vaccination campaigns. Management cautioned that future timing and volume are uncertain and international sales generally generate lower revenue per unit, potentially reducing margins.
- Total unit sales increased 8.5%, but cost of manufactured product rose 38.9%, driven by higher freight costs, product mix and unit volume. Operating expenses increased 27.7%, including $1.1 million of share-based compensation and higher employee and consulting costs.
- Net income included a $3.3 million unrealized gain on equity securities, compared with $1.1 million in Q1 2021. The effective tax rate increased to 43.2% from 26.9%; the filing cites stock compensation, an out-of-period adjustment and a change in state apportionment estimates.
- The $81.0 million TIA funds domestic production expansion. By May 6, 2022, the company reported about $68.7 million received and roughly $64.2 million in negotiated equipment contracts. The amended completion date was August 29, 2022. The company also planned a $5.6 million office expansion, with about $2.0 million spent to date and substantial completion expected in October 2022.
Outlook, risks and contingencies
- No formal revenue or earnings guidance was provided. Management said revenue could decline absent new U.S. government orders and/or increased domestic orders; significant future government orders were uncertain. The prior delivery orders were tied to COVID-19 response and may not indicate future operations.
- Freight and supply-chain challenges have materially increased costs and may continue. The company sourced approximately 93.7% of products from Chinese manufacturers in Q1, creating supplier and geopolitical exposure; alternatives or expanded domestic production may be needed if supply is disrupted.
- New domestic capacity could be underutilized if demand does not materialize. Other stated uncertainties include tariffs, third-party manufacturing costs, production volumes, COVID-19 booster and flu-shot demand, and the ability to pass cost increases through to customers.
- The company’s lawsuit against former legal counsel continued: defendants sought partial summary judgment, a hearing was set for June 3, 2022, and a jury trial for January 30, 2023. The filing does not provide a clear estimate of any potential recovery or loss.
- Approximately $1.4 million in dividends remained payable to former shareholders the company had not yet located. The $10 million repurchase plan was terminated April 14, 2022; total purchases under it were 1,087,145 shares for about $8.1 million.
Important facts for investors to verify
- Whether government and humanitarian-organization orders recur, and the effect of their loss or mix on sales and margins.
- Whether rising freight and manufacturing costs moderate, and whether the company can maintain access to Chinese suppliers.
- Progress, timing, utilization and remaining cash requirements for TIA-funded capacity and the company-funded office expansion.
- The sustainability of earnings excluding investment gains and the unusually high Q1 effective tax rate.
- Developments in the legal case and the status of unpaid dividends to former shareholders.